Pharma industry heavyweights have released their first reports detailing payments to healthcare professionals
The reports give a rundown of each company’s payments to healthcare professionals for “provision of services” and “educational support” between October 2015 and April 2016.
In October 2015, Medicines Australia introduced a Code of Conduct that requires its member companies to collect and report this information.
From 1 October 2016, the Code requires reporting of all these payments to be mandatory.
Medicines Australia enacted the new clause in an effort “to improve accountability and transparency” in the pharmaceutical industry.
“Consumers will be able to better understand the critical interactions that their doctor and other healthcare professionals have with the innovative medicines industry,” says the organisation, which represents its pharmaceutical industry members in Australia.
Payments cover registration fees for events, air travel and accommodation costs, and fees for services and consultancy.
Medicines Australia states that healthcare professionals whose names have been recorded in the reports have given consent to have their relationship with the company publicly released.
On average, nearly two out of three healthcare professionals agreed to have their names reported, says the group.
Most of these are classified as ‘Medical Practitioners’ followed by nurses – with a minimal number of pharmacists scattered through the lists.
For example, Pfizer spent $1.07 million on 230 healthcare professionals who agreed to be named, of which two were pharmacists while the majority were doctors.
AJP compiled some of the total spending amounts for the period October 2015 – April 2016, which are as follows (figures have been rounded up to the nearest ten thousand):
Bristol-Myers Squibb: $1.87 million
Novartis (including Alcon): $1.67 million
Servier Laboratories: $1.29 million
Pfizer: $1.07 million
Gilead Sciences: $844,000
Boehringer Ingelheim: $724,000
View all the reports here